Immatics (IMTX) EBT (2019 - 2025)
Immatics (IMTX) posted EBT of -$41.4 million for Q4 2025, up 30.12% sequentially from -$59.2 million in Q3 2025, and down 189.53% YoY from $46.2 million in Q4 2024.
Immatics (IMTX) EBT (2019 - 2025) Analysis & Trends
Immatics has reported EBT for 7 years, with the latest figure at -$41.4 million in Q4 2025.
- Quarterly EBT fell 189.53% year-over-year to -$41.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$224.4 million (down 1094.55% YoY) and the FY2025 annual result came in at -$224.2 million, down 1070.39% from the prior year.
- EBT grew to -$41.4 million in Q4 2025 per IMTX's latest filing, from -$59.2 million in the prior quarter.
- Over five years, EBT peaked at $96.1 million in Q1 2022 and troughed at -$80.8 million in Q2 2025.
- A 5-year average of -$18.3 million and a median of -$24.0 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT soared 449.38% in 2022, then slumped 2196.9% in 2025.
- Over 5 years, EBT stood at -$19.2 million in 2021, then soared by 44.68% to -$10.6 million in 2022, then sank by 164.82% to -$28.1 million in 2023, then jumped by 264.36% to $46.2 million in 2024, then tumbled by 189.53% to -$41.4 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$41.4 million, -$59.2 million, and -$80.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -41.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.40 Mn |
| Sep 30, 2025 | -59.24 Mn |
| Jun 30, 2025 | -80.76 Mn |
| Mar 31, 2025 | -42.97 Mn |
| Dec 31, 2024 | 46.24 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -19.22 Mn |
| Mar 31, 2024 | -1.87 Mn |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | -10.62 Mn |
| Sep 30, 2022 | -20.55 Mn |
| Jun 30, 2022 | -13.70 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |